Nurix Therapeutics (NRIX) Enterprise Value (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Enterprise Value data on file, last reported at -$443.5 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 8.7% year-over-year to -$443.5 million in Q2 2026; TTM through May 2026 was -$443.5 million, a 8.7% increase from a year earlier, with the FY2025 full-year figure at -$592.9 million, up 2.73% from the prior year.
• Enterprise Value for Q2 2026 stood at -$443.5 million, up from -$540.7 million in the prior quarter.
• Over the last five years, Enterprise Value for NRIX reached as high as -$244.0 million in Q1 2024 and fell as low as -$609.6 million in Q4 2024.
• Historically, Enterprise Value has averaged -$394.7 million across 5 years, with a median of -$386.7 million in 2022.
• Across the five-year window, Enterprise Value increased 24.86% in 2023 and tumbled 125.29% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$309.1 million in 2022, then increased by 6.87% to -$287.9 million in 2023, then plunged by 111.73% to -$609.6 million in 2024, then rose by 2.73% to -$592.9 million in 2025, then increased by 25.2% to -$443.5 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$443.5 million in Q2 2026, -$540.7 million in Q1 2026, and -$592.9 million in Q4 2025.